DepoMed Inc. (DEPO) said that it has received a Paragraph IV certification notice from Lupin Ltd. advising Depomed of the filing of an Abbreviated New Drug Application with the FDA for a generic version of Glumetza, 500 mg and 1000 mg strengths.
Lupin's certification notice alleges that Depomed's patents listed in the FDA Orange Book for Glumetza are invalid and/or will not be infringed by Lupin's commercial manufacture, use or sale of the products described in Lupin's ANDA.
Depomed said it is evaluating the Paragraph IV certification and continues to have full confidence in the intellectual property protecting Glumetza.
Depomed has 45 days to commence a patent infringement lawsuit against Lupin that would automatically stay, or bar, the FDA from approving Lupin's ANDA for 30 months or until a district court decision that is adverse to the company, whichever is earlier.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.